Proteasome inhibitor drugs on the rise
Proteasome inhibitor drugs on the rise
复制标题
DOI：
10.1158/0008-5472.can-06-2033
复制
发表时间：
2006-08-15
期刊：
影响因子：
11.2
通讯作者：
Hunter, Tony
中科院分区：
文献类型：
--
作者：
Joazeiro, Claudio A. P.;Anderson, Kenneth C.;Hunter, Tony
2003年5月，美国食品和药物管理局批准蛋白酶体抑制剂硼替佐米（Velcade）快速通道状态用于治疗多发性骨髓瘤。这一里程碑代表了靶向泛素-蛋白酶体系统（UPS）的药物首次获批用于任何适应症。最近，在AACR特别会议“泛素和癌症：从分子靶点和机制到临床”（奥兰多，佛罗里达州，2006年1月18日至22日）上，很明显UPS中的药物发现正在经历另一轮巨大的兴奋。原因是硼替佐米的新的临床应用，沿着新型蛋白酶体抑制剂进入临床的成功。
In May 2003, the U.S. Food and Drug Administration granted the proteasome inhibitor bortezomib (Velcade) fast-track status for the treatment of multiple myeloma. This landmark represented the first approval of a drug targeting the ubiquitin-proteasome system (UPS) for any indication. More recently, at the AACR Special Conference "Ubiquitin and Cancer: From Molecular Targets and Mechanisms to the Clinic" (Orlando, FL, January 18-22, 2006), it became evident that drug discovery in the UPS is experiencing another round of great excitement. The reason-new clinical applications found for bortezomih, along with the promised success of new types of proteasome inhibitors reaching the clinic.